Search

Search Constraints

You searched for: Author/Creator Semba, Taro

Search Results

2. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Issue 10 (16th September 2014)

3. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor. Issue 6 (28th April 2014)

4. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. (June 2022)